Tower Research Capital LLC TRC Has $751,000 Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Tower Research Capital LLC TRC lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 816.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,458 shares of the company's stock after buying an additional 56,534 shares during the period. Tower Research Capital LLC TRC's holdings in Roivant Sciences were worth $751,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of Roivant Sciences in the fourth quarter worth $39,000. GAMMA Investing LLC boosted its position in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Roivant Sciences by 84.1% during the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after purchasing an additional 3,426 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insiders Place Their Bets

In related news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the completion of the sale, the chief operating officer now owns 1,116,345 shares of the company's stock, valued at $11,409,045.90. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,395,541 shares of company stock worth $14,922,538 in the last 90 days. 7.90% of the stock is owned by company insiders.

Roivant Sciences Stock Performance

Roivant Sciences stock traded up $0.05 during midday trading on Friday, reaching $11.63. The company's stock had a trading volume of 4,325,649 shares, compared to its average volume of 5,490,770. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The firm has a market capitalization of $8.30 billion, a PE ratio of -77.43 and a beta of 1.25. The stock's 50 day simple moving average is $10.40 and its 200 day simple moving average is $11.14.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.